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Hippocampal and behavioral dysfunctions in a mouse model
of environmental stress: normalization by agomelatine
F Boulle1,2,3,4, R Massart5, E Stragier1,6, E Païzanis1,6, L Zaidan1,6, S Marday1,6, C Gabriel7, E Mocaer7, R Mongeau1,4 and L Lanfumey1,6
Stress-induced alterations in neuronal plasticity and in hippocampal functions have been suggested to be involved in the
development of mood disorders. In this context, we investigated in the hippocampus the activation of intracellular signaling
cascades, the expression of epigenetic markers and plasticity-related genes in a mouse model of stress-induced hyperactivity and of
mixed affective disorders. We also determined whether the antidepressant drug agomelatine, a MT1/MT2 melatonergic receptor
agonist/5-HT2C receptor antagonist, could prevent some neurobiological and behavioral alterations produced by stress. C57BL/6J
mice, exposed for 3 weeks to daily unpredictable socio-environmental stressors of mild intensity, were treated during the whole
procedure with agomelatine (50 mg kg− 1 per day, intraperitoneal). Stressed mice displayed robust increases in emotional arousal,
vigilance and motor activity, together with a reward deﬁcit and a reduction in anxiety-like behavior. Neurobiological investigations
showed an increased phosphorylation of intracellular signaling proteins, including Atf1, Creb and p38, in the hippocampus of
stressed mice. Decreased hippocampal level of the repressive epigenetic marks HDAC2 and H3K9me2, as well as increased level of
the permissive mark H3K9/14ac suggested that chronic mild stress was associated with increased gene transcription, and clear-cut
evidence was further indicated by changes in neuroplasticity-related genes, including Arc, Bcl2, Bdnf, Gdnf, Igf1 and Neurod1.
Together with other ﬁndings, the present data suggest that chronic ultra-mild stress can model the hyperactivity or psychomotor
agitation, as well as the mixed affective behaviors often observed during the manic state of bipolar disorder patients. Interestingly,
agomelatine could normalize both the behavioral and the molecular alterations induced by stress, providing further insights into
the mechanism of action of this new generation antidepressant drug.
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INTRODUCTION
Stress is a predisposing factor for a broad range of behavioral and
pathophysiological disturbances, among which mood disorders
are most frequent.1 More speciﬁcally, the hippocampus—a key
region in emotional and cognitive processes—is known to be
highly sensitive to glucocorticoids in line with the important role
of this limbic structure in the integration of the stress response.2,3
Although the timing and intensity of stressors seem to be critical
for the neuroendocrine and behavioral outcomes, the exact
mechanism by which stress modulates functional and structural
plasticity in the hippocampus and other brain areas remains
incompletely known.4 To date, it is well accepted that severe and
long-lasting traumatic stress can lead to neuronal loss and
synaptic dysfunction in the hippocampus, in association with
low mood, anxiety and impaired cognition, which constitute core
symptoms of major depression.5,6 Furthermore, stressful life
events can also precipitate manic episodes in bipolar disorder
patients characterized by elevated mood, hyperactivity, impulsiv-
ity and increased vigilance.7,8
At the molecular level, the sustained elevation of glucocorti-
coids observed during stressful situations might interfere with
various intracellular signaling and transcriptional processes. In
particular, chromatin remodeling via histone modiﬁcations occurs
in response to diverse environmental variations and represents a
key regulator of nuclear integration promoting structural and
functional adaptations necessary for neuronal plasticity.9 Hence,
during the past decade, epigenetic mechanisms have emerged as
a key process by which environmental variations could leave
persistent imprints on gene expression increasing the risk of
mood disorders.10 In addition, antidepressants and mood
stabilizers have been shown to mediate their therapeutic effects,
at least in part, through epigenetic remodeling.10,11
More recently, agomelatine, an agonist at melatonergic
receptor 1 (MT1) and 2 (MT2) and a 5-HT2C receptor antagonist,
has emerged as an efﬁcient treatment for major depressive
episodes.12 Several studies have shown that these receptors are
present in brain areas involved on mood as the hippocampus, the
cortex and the amygdala. Indeed, MT1 and MT2 melatonin
receptors are present in the dentate gyrus, CA3 and CA1 regions,
and the subiculum of the hippocampal formation.13 Similarly, in
this area, 5-HT2C receptors have high expression in the rostral CA3
pyramidal ﬁeld layer, in the strata oriens and radiatum of the
caudal CA1 area, and in the ventral subiculum.14 At the preclinical
level, most of the data supported the fact that the antidepressant-
like effects of agomelatine depend on the synergy between
melatonergic agonist and 5-HT2C antagonist properties.15,16
Agomelatine is also thought to exert many of its effects via a re-
synchronization of circadian rhythms.12 Disruption of circadian
periodicity being a major factor for the onset of bipolar
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disorders,17,18 agomelatine might be endorsed with therapeutic
potentialities for bipolar disorders beside unipolar depression.
We previously reported that the chronic ultra-mild stress
(CUMS) procedure (that consists of prolonged repetition of low-
intensity stressors, including social isolation, perturbations of
circadian rhythms and alteration of daily life habits) induces
affective-like disorders associated with impulsive choice in the
decision making task in adult mice.19,20 In the present study, we
aimed at further characterizing the manic-like phenotype, as well
as exploring intracellular signaling, epigenetic regulations and
genes transcription proﬁle of CUMS-exposed mice. In addition, we
tested the ability of agomelatine to restore a normal phenotype
and reverse the stress-induced cellular and molecular alterations
of these mice.
MATERIALS AND METHODS
Animals
Experiments were performed using 10- to 12-week-old C57BL/6J male
mice (Charles River Laboratories, l′Arbresle, France) of 25–30 g body
weight. Upon arrival in the laboratory, mice were housed in groups of four
per cage under standard conditions (22± 1 °C, 60% humidity, 12-h light–
dark cycle with lights on at 0700 h, food and water ad libitum) for 1 week
before the beginning of experiments. Procedures involving animals and
their care were conducted in conformity with the institutional guidelines
that are in compliance with national and international laws and policies
(Directive 2010/63/UE, 22/09/2010, protocol ID 00966.01).
Stress, treatments
The CUMS procedure in mice is detailed elsewhere.19,20 It is a modiﬁed
version of the chronic mild stress protocol originally designed for rats.21
Brieﬂy, mice (three batches of 16 stressed mice, CUMS) were subjected to
daily socio-environmental stressors of low intensity, in an unpredictable
manner (See Supplementary Table S1 and Supplementary Figure S1)
during a 25-day period. Administration of compounds was initiated at the
beginning of this stress procedure, every day at 1800 h (that is, 1 h before
the onset of dark period), up to the 25th day. Agomelatine (50mg kg− 1,
Servier, Suresnes, France) and its vehicle (hydroxyethylcellulose; HEC 1%,
Servier) were administered intraperitoneally as described in previous
studies.22 The control, non-stressed mice (three batches of 16 mice, NS)
groups received the same treatments (HEC versus agomelatine) in the
same conditions.
Behavioral tests
Behavioral tests were performed within the fourth week of stress, with a
delay of at least 18 h after the last stressor, so as to avoid an eventual effect
of acute stress. Animals were kept in the testing room at least 2 h before
the test to allow habituation to the new environment.
The behavioral tests (see Supplementary Methods) were adapted from
existing protocols. Classical tests for measuring behaviors relevant to
depression (tail suspension test (TST); forced swim test (FST); splash test;
saccharin intake), locomotor activity (rotarod; open ﬁeld (OF); actimetry)
and anxiety-like behaviors (elevated plus maze (EPM); OF), were performed
between day 21 and day 25.
Finally, animals were killed on day 26, and their brains were kept at
− 80 °C until use.
Real-time quantitative reverse transcriptase-PCR
Total mRNA was extracted from the entire hippocampus using the
NucleoSpin RNA II kit (Macherey-Nagel, Hoerdt, France), and subsequent
cDNA synthesis was performed using a High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Courtaboeuf, France) according to
the manufacturer’s protocol. One part of the ampliﬁcation was made with
Absolute SYBR Green ROX Mix (Thermo Scientiﬁc, Illkirch, France) using the
7300 real-time PCR System (Applied Biosystems), and the other part using
TaqMan (Applied Biosystems). The sequences of primers used are
indicated in Supplementary Tables S2 and S3. The 2ΔΔCT (delta-delta
comparative threshold) method was used to normalize the fold change in
gene expression determined with both quantitative PCR technologies.
Western blots
Total hippocampi were lysed in ice-cold lysis buffer (1% Triton X-100,
150mM NaCl, 1 mM EDTA, 10mM Tris, pH 8.0, 10%, 10mM NaF, 1 mM sodium
orthovanadate and protease inhibitors cocktail). Protein extracts were
loaded on a SDS–PAGE gel for electrophoresis migration and separated
bands were transferred to a polyvinylidene diﬂuoride membrane for 7 min
using the iBlot gel transfer system (Life Technologies, St Aubin, France).
Nonspeciﬁc binding of antibodies was prevented by preincubating the
membranes in a blocking buffer (phosphate-buffered saline-Tween 0.01%
supplemented with BSA 5%, w/v) for 1 h at room temperature. Then,
membranes were incubated overnight at 4 °C in the same blocking buffer
supplemented with the primary antibody (see Supplementary Table S4).
After extensive washing, membranes were subsequently incubated with
appropriate ﬂuorescent secondary antibodies (Alexa Fluor 488 goat anti-
rabbit or Alexa Fluor 488 donkey anti-mouse; Molecular Probes, Eugene,
OR, USA) for 1 h at room temperature. Finally, membranes were washed,
dried and scanned using the Odyssey infrared imaging system (Westburg,
Leusden, The Netherlands). The intensity of bands of interest was
quantiﬁed using ImageJ software. The quantity of proteins loaded on gel
was controlled using the housekeeping protein β-tubulin (Cell Signaling
Technology, Saint-Quentin-en-Yvelines, France).
Immunohistochemistry
Brain coronal sections (20 μm thick) were collected at the level of the
hippocampus (according to Franklin and Paxinos’ atlas),23 using a cryostat,
directly mounted on Superfrost Plus slides (Thermo Scientiﬁc) and stored
at − 80 °C until use. On the labeling day, sections were ﬁrst ﬁxed with 4%
paraformaldehyde at 4 °C for 10min. After blocking nonspeciﬁc binding
with BSA 0.4 and 5% of the appropriate serum, and permeabilizing cell
membranes with 0.05% of Tween 20, the sections were incubated
overnight at 4 °C with the primary antibodies (see Supplementary Table
S4). On the following day, sections were incubated for 1 h at room
temperature in the presence of the appropriate biotinylated secondary
antibodies, and the reaction was ampliﬁed using the ABC staining system
(Vectastain ABC Elite Kit, Vector Laboratories, Les Ulis, France) for one
additional hour. Finally, sections were treated with 3,3′-diaminobenzidine
(Sigma FAST, D4293, Sigma-Aldrich, Saint Quentin-Fallavier, France) for
revealing speciﬁcally bound antibodies. After dehydrating the sections and
mounting with cover slip, pictures were taken with an optic microscope
(Olympus BX21, zoom 4 and 10) and optical densities were measured and
then normalized using the ImageJ software (National Institutes of Health,
Bethesda, MD, USA).
Statistical analyses
Data are represented as mean± s.e.m. The Student’s t-test was used for
comparison between two groups (Prism 5.0, GraphPad software, USA).
When more than two groups were compared, the two-way analysis of
variance (stress × treatment) was used, followed by the Bonferroni post hoc
test. When necessary, a planned pairwise comparison was made using
Dunn’s t-test. The critical level of signiﬁcance was set at Po0.05.
RESULTS
At the end of the chronic stress period, a battery of well-
established behavioral tests aiming at measuring locomotor
behavior (actimetry, rotarod, OF), anxiety-related behaviors (EPM,
OF) and depression-related behaviors (Splash test, saccharin
intake, TST, FST) was used to assess CUMS-induced behavioral
alterations. Behavioral investigations showed that stressed mice
exhibit robust increases in emotional arousal, vigilance and motor
activity, together with a reduction in anxiety and a reward deﬁcit.
Most of these behavioral impairments could be normalized by
chronic agomelatine treatment. To further elucidate the molecular
and cellular mechanisms associated with CUMS, we investigated
the activation of intracellular signaling cascades by western blots,
the expression of epigenetic markers by immunohistochemistry
and the expression of plasticity-related genes by reverse
transcriptase-PCR in the hippocampus. Marked increase in some
intracellular signaling pathways, together with a permissive
chromatin state and an increased gene expression were observed
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in the hippocampus of stressed mice. Chronic treatment with
agomelatine corrected most of these neurochemical alterations.
Agomelatine prevents stress-induced behavioral alterations
At the end of the stress period, animals displayed a pronounced
hyperactivity, as shown by the increased exploration in the OF
arena (Figure 1a, +30.0 ± 6.4%), especially during the ﬁrst minutes
of the test (Figure 1a, upper panel). This increased motor activity
was conﬁrmed by measuring spontaneous locomotion in an
actimetry box. The ambulation, corresponding to the number of
crossings in the center of the actimetry box (Figure 1b), was
signiﬁcantly increased in stressed mice (+82.0 ± 11.5%). The
number of rearings, corresponding to a vertical activity where
the mouse had the forefeet up, was also increased after exposure
to stress (+95.0 ± 12.5%, Figure 1b). Similarly, the distance covered
in the EPM test was increased in mice subjected to chronic mild
stress (+20.0 ± 7.6%, Supplementary Figure S2). In addition, the
performance in the rotarod test was altered in stressed mice, as
shown as a decrease in the latency to fall (−39.0 ± 9.5%,
Supplementary Figure S3) indicating impairment of movement
coordination.
Interestingly, stress-induced alterations in the distance covered
in the OF, as well as the numbers of crossings and rearings in
actimetry boxes were signiﬁcantly reduced by chronic adminis-
tration of agomelatine (Figures 1a and b).
Furthermore, we assessed a reward-related behavior by
measuring the consumption of saccharin solution and the time
spent in self-grooming in CUMS versus non-stressed mice. Data in
Figure 2 indicate that CUMS signiﬁcantly decreased both saccharin
intake and grooming behavior (−35.0 ± 6.5% and − 43.0 ± 7.6%,
respectively, Figures 2a and b), and here too, chronic treatment
with agomelatine brought these behaviors back to those
displayed by non-stressed mice (Figures 2a and b). It is noteworthy
that the CUMS procedure did not modify water consumption and
body weight (Supplementary Figure S4).
Finally, we also performed validated tests to measure the
defense-related behaviors and anxiety levels using the TST, the
FST, the OF test and the EPM test (Figure 2). CUMS signiﬁcantly
reduced the immobility time in the TST (−52.0 ± 11.7%, Figure 2c),
and this effect was prevented by chronic agomelatine. In contrast,
the immobility time in the FST did not differ in CUMS versus non-
stressed mice (Figure 2d). However, small increases in the overall
mobility and the number of activity bursts were observed in the
FST after the chronic stress exposure (+9.0 ± 4.8% and
+16.0 ± 7.2%, respectively, Figures 2d and e). The mobility duration
and the number of activity bursts were signiﬁcantly different in
stressed mice treated with agomelatine versus those treated with
vehicle (Figures 2d and e), indicating an effect of agomelatine on
escape-like behaviors in this paradigm. In the OF, CUMS mice were
apparently more prone to explore the center than non-stressed
mice as shown by a higher number of entries of the former group
in the center (+46.0 ± 12.4%, Figure 2f). Here too, chronic
administration of agomelatine tended to prevent this CUMS-
induced behavioral change, although the difference was not
signiﬁcant (Figure 2f).
Altogether, these behavioral analyses indicated that CUMS
caused a marked hyperactivity, together with increase in defense
Figure 1. Effects of chronic agomelatine treatment on stress-induced locomotor dysfunction. (a) Stressed (CUMS) and non-stressed (NS) mice
were placed in an open ﬁeld test, and the distance covered in the arena was measured over time (top panel). In the bottom panel, the total
distance covered for the 20-min test period is represented. Two-way analysis of variance (ANOVA) indicated a signiﬁcant effect of stress (F
(1,28)= 5.78; Po0.05), but no effect of treatment (F(1,28)= 2.95; P40.05). However, there was a signiﬁcant interaction between the stress and
the treatment factors (F(1,28)= 6.89; Po0.05), and the Bonferroni post hoc test revealed a signiﬁcant increase in the distance covered by
stressed mice (Po0.01), prevented by agomelatine (AGO, Po0.01). (b) Mice were placed in actimetry boxes, and the numbers of crossings in
the center of the apparatus, as well as the numbers of rearings were measured with an infrared device over 1 h (top panel). In the bottom
panel, the total numbers of crossings and total numbers of rearings over the 1-h test period are indicated. Two-way ANOVA indicated a
signiﬁcant effect of stress on both crossing activity (F(1,28)= 15.21; Po0.01) and rearing activity (F(1,28)= 9.12; Po0.001). A signiﬁcant
interaction between the stress and the treatment factors on crossing (F(1,28)= 7.30; Po0.05) and rearing behaviors (F(1,28)= 12.43; Po0.01)
was observed. Bonferroni post hoc test revealed a signiﬁcant increase in the crossings and rearings in stressed mice (Po0.001), which could be
prevented by agomelatine (Po0.01 and Po0.001, respectively). Data are expressed as mean± s.e.m of n= 8 mice per group. **,§§Po0.01;
***,§§§Po0.001. CUMS, chronic ultra-mild stress; HEC, hydroxyethylcellulose.
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mechanisms and a decrease in feeding-related behavior. All these
behavioral alterations were prevented when mice were treated
with agomelatine (50 mg kg− 1 per day) during the whole stress
procedure.
Agomelatine prevents stress-induced alterations in intracellular
signaling cascades
To further elucidate the cellular mechanisms associated with
CUMS, we investigated the hippocampal intracellular signaling
pathways involved in cell survival, proliferation and differentiation
in stressed versus non-stressed mice. As shown by the western
blot analyses (Figure 3), CUMS altered several hippocampal
intracellular signaling pathways.
Phosphorylation of the protein kinase B (Akt), the extracellular
signal-regulated kinase (Erk), the p38 mitogen-activated protein
kinase (p38), the cAMP response element-binding protein (Creb),
and the activating transcription factor 1 (Atf1) were all increased in
CUMS-exposed mice (+16.7 ± 6.2%, +22.1 ± 8.0%, +71.4 ± 14.6%,
+41.9 ± 10.5% and +54.6 ± 14.8%, respectively, Figure 3). In
contrast, TrkB phosphorylation was not signiﬁcantly changed by
CUMS. As shown in Figure 3, the CUMS-induced increases in
phospho-Akt, phospho-Erk, phospho-p38 and phospho-Creb were
completely suppressed by chronic treatment with agomelatine.
Figure 2. Effects of chronic agomelatine treatment on stress-induced affective behaviors. (a) Saccharin consumption was measured for an
overnight period. There was a signiﬁcant interaction between the stress and the treatment factors (F(1,39)= 8.29; Po0.01), and the Bonferroni
post hoc test revealed a signiﬁcant decrease in the saccharin intake of stressed mice (Po0.05), prevented by agomelatine (Po0.001). (b) The
time spent in grooming behavior over a total period of 5 min was measured in mice subjected to the splash test. Two-way analysis of variance
(ANOVA) indicated a signiﬁcant effect of stress (F(1,70)= 13.9; Po0.01), as well as treatment (F(1,70)= 7.62; Po0.05) on grooming behavior.
The Bonferroni post hoc test revealed a signiﬁcant decrease in the self-grooming of stressed mice (Po0.01) prevented by agomelatine
(Po0.01). (c) The immobility time in the tail suspension test paradigm was measured in both control (NS) and CUMS-exposed mice. Two-way
ANOVA indicated a signiﬁcant effect of stress (F(1,30)= 7.69; Po0.01) and treatment (F(1,30)= 16.59; Po0.001) on immobility time. There was
a signiﬁcant interaction between the stress and the treatment (F(1,30)= 4.55; Po0.05), and the Bonferroni post hoc test revealed a signiﬁcant
decrease in the immobility time of stressed mice (Po0.01) prevented by agomelatine (Po0.001). (d, e) Mice were subjected to the forced
swim test, and the time spent in the swimming activity (mobility) and the struggling activity (number of bursts) over a 6-min period are
represented. There was a signiﬁcant interaction between the stress and the treatment factors (F(1,26)= 4.25; Po0.05) for the mobility time,
and the Bonferroni post hoc test revealed a signiﬁcant decrease in the mobility time of stressed mice treated with agomelatine as compared
with stressed mice treated with vehicle (Po0.05). A tendency toward an interaction between the stress and the treatment factors for the
number of bursts (F(1,26)= 3.12; P= 0.089) was observed, and a planned pairwise comparison using Dunn’s t-test indicated a signiﬁcant
decrease in the number of bursts of stressed mice treated with agomelatine as compared with stressed mice treated with vehicle (Po0.05). (f)
Mice were subjected to an open ﬁeld test, and the number of visits to the center of the arena was measured over a 20-min period. There was a
signiﬁcant interaction between the stress and the treatment (F(1,26)= 5.94; Po0.05), and the Bonferroni post hoc test revealed a signiﬁcant
increase in the number of entries into the center of the arena in stressed mice (Po0.05). Data are expressed as mean± s.e.m. of n= 7–12 mice.
*,§Po0.05; **,§§Po0.01; ***,§§§Po0.001. AGO, agomelatine; CUMS, chronic ultra-mild stress; HEC, hydroxyethylcellulose; NS, non-stressed.
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Altogether, western blot investigations showed that speciﬁc
effectors of the mitogen-activated protein kinases and PI3-K
pathways, involving Akt, Erk, p38, Creb and Atf1, were increased
after CUMS, and that agomelatine could prevent most of these
changes.
Agomelatine prevents stress-induced changes in the expression of
neuroplasticity-related genes and epigenetic regulations
The expression of various genes involved in neuronal plasticity,
and genes implicated in the regulation of transcription or
epigenetic regulation were also measured (Supplementary
Tables S5–S7). First, qPCR screening (Supplementary Table S5)
revealed that chronic stress promoted hippocampal expression of
several plasticity-related genes including the brain-derived
neurotrophic factor (Bdnf) gene (+28 ± 7%), the neurogenic
differentiation 1 (Neurod1) gene (+69 ± 10%), the insulin growth
factor 1 (Igf1) gene (+41 ± 7%), the activity-regulated cytoskeleton-
associated protein (Arc) gene (+56 ± 10%), the glial cell-derived
neurotrophic factor (Gdnf) gene (+58 ± 15%) and the b-cell
lymphoma 2 (Bcl2) gene (+46 ± 9%). In addition, the expression
of the nuclear receptor subfamily 1, group D, member 2 (Nr1d2),
known as a transcription activator, was also higher (+40 ± 5%,
Supplementary Table S6), whereas the expression of the nuclear
receptor co-repressor 1 (Ncor1), known as a transcription
repressor, was lower (−37± 6%, Supplementary Table S6) in CUMS
versus non-stressed mice. This general increase in all these
plasticity-related genes occurred in conjunction with an increase
in hippocampal cell proliferation within the gyrus dentus, at day
21 of the CUMS session (Supplementary Figure S5).
A screening for modulations of epigenetic markers involved in
synaptic plasticity including histone deacetylases, DNA methyl-
transferases, methyl binding domain protein and histone acetyl-
transferase was also performed (Supplementary Table S7). A
signiﬁcant CUMS-induced reduction of the epigenetic repressor
Hdac2 (−22 ± 4%, Supplementary Table S7)—a key player in
hippocampal plasticity—was observed. Hence, on one hand, we
decided to further investigate the expression of epigenetic
markers, and measured the expression of HDACs and posttransla-
tional modiﬁcations at histone tails (Supplementary Figures S6–
S8). As shown by immunostaining analyses, CUMS decreased
HDAC2 protein levels, but not those of HDAC1, in hippocampal
CA1 and CA3 subﬁelds (−18.0 ± 1.2% and − 14.0 ± 4.3%, respec-
tively, Supplementary Figure S5A). On the other hand, the
expression of histone 3 lysine 9 di-methylated (H3K9me2) was
speciﬁcally decreased in the CA3 region (−23.0 ± 4.3%,
Supplementary Figure S6A), whereas the expression of histone 3
lysine 9 and 14 acetylated (H3K9/14ac) was increased in the CA1
Figure 3. Effects of chronic agomelatine treatment on intracellular signaling in the hippocampus of stressed mice. Western blot analyses of
phospho-Akt, phospho-Erk, phospho-p38, phospho-Creb, phospho-Atf1 and phospho-TrkB were performed on hippocampal extracts. Two-way
analysis of variance revealed a signiﬁcant interaction between stress and treatment factors for p-p38 (F(1,12)= 16.22; Po0.001), p-Creb (F
(1,28)= 10.63; Po0.01) and p-Atf1 (F(1,11)= 5.19; Po0.05). There was a signiﬁcant effect of treatment on p-Akt (F(1,26)= 13.72; Po0.001), p-Erk
(F(1,14)= 23.82; Po0.001), p-p38 (F(1,12)= 18.35; Po0.01) and p-Creb (F(1,28)= 6.49; Po0.05), and an effect of stress on p-p38 (F(1,12)= 11.77;
Po0.01). A trend for a stress effect was observed for p-Akt (F(1,26)= 4.09; P= 0.053), p-Erk (F(1,14)= 4.55; P= 0.051) and p-Atf1 (F(1,11)= 3.55;
P= 0.086). The Bonferroni post hoc analyses revealed a signiﬁcant difference between non-stressed mice treated with vehicle (NS HEC) and
stressed mice treated with vehicle (CMS HEC) for the levels of p-p38 (Po0.001), p-Creb (Po0.05) and p-Atf1 (Po0.05). Agomelatine treatment
(50mg kg− 1 per day) prevented the phosphorylation of p38 (Po0001) and Creb (Po0.001) induced by stress (CMS HEC versus CMS AGO). In
addition, agomelatine decreased p-Akt (Po0.05) and p-Erk (Po0.05) in stressed mice (CMS HEC versus CMS AGO). Data are expressed as
percentage of non-stressed mice treated with vehicle (NS HEC), and each bar represents the mean7s.e.m. (n= 4–8 mice). *,§Po0.05;
**,§§Po0.01; ***,§§§Po0.001. AGO, agomelatine; CUMS, chronic ultra-mild stress; HEC, hydroxyethylcellulose; NS, non-stressed.
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and CA3 subﬁelds (+63.0 ± 12.5% and +32.0 ± 12.5%, respectively,
Supplementary Figure S7B) in mice that had been exposed to
CUMS. In contrast, the expression of histone 4 acetylated (H4ac)
and that of histone 3 lysine 4 tri-methylated (H3K4me3) were not
affected by CUMS (Supplementary Figures S7C and S7D).
The ability of agomelatine to correct these important CUMS-
induced epigenetic modiﬁcations in the hippocampus was
investigated. Data in Figure 4 show that chronic treatment with
agomelatine signiﬁcantly prevented the stress-mediated decrease
in HDAC2 and H3K9me2, as well as the stress-induced increase in
H3K9/14ac in the CA3 region of the hippocampus. The action of
agomelatine was rather speciﬁc of the CA3 subﬁeld, as no
signiﬁcant effects were observed in the CA1 and DG subﬁelds
(Supplementary Figure S8). In a similar manner, some of the
alterations in plasticity-related gene expression observed after
CUMS exposure were normalized by the chronic agomelatine
treatment (Figure 5). In particular, agomelatine signiﬁcantly
restored expression of the Bdnf gene, the Neurod1 gene, the Igf1
gene and the Arc gene to the levels observed in non-stressed
mice. CUMS-induced expressions of the Gdnf gene and the Bcl2
gene were not signiﬁcantly affected by agomelatine treatment.
Altogether, these data indicate that CUMS triggered marked
histone posttranslational changes, favoring chromatin open state.
Interestingly, this permissive state of chromatin was associated
with increased transcription of genes involved in neuroplasticity,
and concomitant treatment with agomelatine could abolish most
of these CUMS-induced changes.
DISCUSSION
Substantial evidence has been accumulated to suggest that
stressful life events might trigger mood disorders and that
successful antidepressant treatments might involve a normal-
ization of stress-related alterations in cortico-limbic structures.24,25
Figure 4. Effects of chronic agomelatine treatment on epigenetic marks in the hippocampus of stressed mice. Representative
photomicrographs of HDAC2 (a), H3K9me (b) and H3K9ac (c) immunolabelings in the CA3 subﬁeld of the hippocampus are shown in the
left panels, and the quantiﬁcation of respective optical density values in the right panel. (a) Two-way analysis of variance (ANOVA) indicated a
signiﬁcant effect of stress (F(1,16)= 5.76; Po0.05), but no effect of treatment (F(1,16)= 2.02; P40.05) for the repressive mark HDAC2. There
was a signiﬁcant interaction between the stress and the treatment (F(1,16)= 5.17; Po0.05), and the Bonferroni post hoc test revealed a
signiﬁcant decrease in HDAC2 immunolabeling in the CA3 subﬁeld in CUMS mice (Po0.01), prevented by agomelatine (Po0.05). (b) Two-way
ANOVA analysis indicated a signiﬁcant effect of treatment (F(1,17)= 4.75; Po0.05), but no effect of stress (F(1,17)= 3.46; P40.05) for the
repressive mark H3K9me. There was a signiﬁcant interaction between the stress and the treatment (F(1,17)= 6.83; Po0.05), and the
Bonferroni post hoc test revealed a signiﬁcant decrease in H3K9me immunolabeling in the CA3 subﬁeld in CUMS mice (Po0.05), prevented by
agomelatine (Po0.01). (c) Two-way ANOVA analysis indicated a signiﬁcant effect of stress (F(1,16)= 5.25; Po0.05) and a tendency for an effect
of treatment (F(1,16)= 3.71; P= 0.072) for the repressive mark H3K9ac. There was a signiﬁcant interaction between the stress and the
treatment (F(1,16)= 9.86; Po0.01), and the Bonferroni post hoc test revealed a signiﬁcant increase in H3K9ac labeling in the CA3 subﬁeld in
CUMS mice (Po0.01), prevented by agomelatine (Po0.01). Quantiﬁcations of immunolabelings are expressed as arbitrary units and each bar
is the mean7s.e.m. of n= 5–6 mice. *,§Po0.05; **,§§Po0.01. AGO, agomelatine; CUMS, chronic ultra-mild stress; HEC, hydroxyethylcellulose;
NS, non-stressed.
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In this context, the aim of the present study was to investigate the
effect of prolonged socio-environmental stressors of low intensity
on depression-related behaviors and hippocampal function in
mice, and explore the biological mechanisms and therapeutic
potentialities of agomelatine in this stress model.
Effects of stress on neuroplasticity and behavior
The data reported herein clearly show that a CUMS induces a
decrease in saccharin consumption, reﬂecting anhedonia, a core
symptom of depression, as observed after other chronic stresses.21
A decrease in grooming was also claimed to be relevant to
depression as it is decreased by chronic stress, an effect reversed
by classical antidepressant drugs.26 Here, we show that both
saccharin consumption and grooming are also reversed by chronic
agomelatine (Figure 2). We also found that CUMS caused a robust
decrease of immobility in the TST, and an increased mobility and a
greater number of burst activity in the FST. Many behavioral
reactions in the TST and the FST can be seen as the expression of
active defense mechanisms in reaction to the aversive challenge
of the environment.27,28 Hence, in our experiments, CUMS
exposure facilitated the ﬂight response as shown by tonic/
energetic burst activity, which might be interpreted as an
excessive emotional arousal and a high vigilance state.29 In
addition, stressed mice displayed a reduced anxiety-like behavior
in the open ﬁeld test and an increased locomotor and motor
activity, reﬂecting a hyperactive state and risk-taking behaviors.
Earlier reports, including those using the similar CUMS procedure
in mice,19,20,29 also mentioned an increased locomotor activity
following chronic mild stress exposure in rodents, which might be
equally interpreted as psychomotor agitation relevant to mood
disorders see also Gronli et al.30 Because convergent studies
demonstrated that physical activity could signiﬁcantly enhance
hippocampal neurogenesis and plasticity,31 the increased loco-
motor activity observed in our study after chronic stress might be
tentatively related to the enhancement of hippocampal plasticity,
as illustrated by the enhanced expression of neuroplasticity
markers (p-Akt, p-Erk, p38, p-Creb, p-Atf1) and increased cell
proliferation. Nevertheless, stressed mice also displayed a
pronounced impairment in motor coordination probably due to
CUMS-induced distractibility and reduced ability to focus on the
task.29
At the neurobiological level, chronic mild stress activates
hippocampal intracellular signaling pathways, such as mitogen-
activated protein kinases known to be involved in neuronal
survival, differentiation and proliferation.32 In addition, we found
robust changes in epigenetic regulation and gene transcription.
CUMS-induced increase in chromatin permissive state and
plasticity-related gene expression might correspond to the nuclear
events downstream of activated intracellular signaling cascades.
Among CUMS-associated epigenetic modiﬁcations, we observed a
signiﬁcant decrease in both mRNA and protein levels of the
transcriptional repressor HDAC2. This is in line with previous
studies showing that low levels of HDAC2 in the hippocampus is
associated with enhanced synaptic plasticity.33 Changes of
histone-modifying enzymes in the hippocampus have been
observed following exposure to severe stressors, for example,
social defeat stress, or exposure to environmental adversity during
development, for example, prenatal stress and maternal separa-
tion in rodents.34–36 Interestingly, the present study is the ﬁrst to
demonstrate that prolonged exposure to low-intensity stressors at
adulthood can trigger sustained alterations of histone
Figure 5. Effects of chronic agomelatine treatment on plasticity-related gene expression in the hippocampus of stressed mice. mRNA levels of
plasticity-related genes, measured by quantitative real-time reverse transcriptase-PCR, are expressed as fold changes compared with non-
stressed mice treated with hydroxyethylcellulose (NS HEC). Two-way analysis of variance indicated a signiﬁcant interaction between stress and
treatment factors for Neurod1 (F(1,32)= 4.80; Po0.05), Igf1 (F(1,34)= 6.15; Po0.05) and Arc (F(1,29)= 7.05; Po0.05). In addition, there was also
an effect of stress on Neurod1 (F(1,32)= 14.41; Po0.001), Igf1 (F(1,34)= 13.30; Po0.001), Gdnf (F(1,25)= 56.71; Po0.001) and Bcl2 (F
(1,26)= 12.47; Po0.01) and a treatment effect on Bdnf (F(1,31)= 17.16; Po0.001), Neurod1 (F(1,32)= 21.05; Po0.001), Arc (F(1,29)= 4.50;
Po0.05) and Gdnf (F(1,25)= 5.57; Po0.05). The Bonferroni post hoc tests indicated a signiﬁcant increase of Bdnf (Po0.05), Neurod1 (Po0.001),
Igf1 (Po0.001), Arc (Po0.05), Gdnf (Po0.001) and Bcl2 (Po0.05) in stressed mice treated with vehicle (CUMS HEC) compared with non-
stressed mice treated with vehicle (NS HEC). Similarly, there was a signiﬁcant difference between stressed mice treated with vehicle (CUMS
HEC) and stressed mice treated with agomelatine (CUMS AGO) for Bdnf (Po0.001), Neurod1 (Po0.001), Igf1 (Po0.05) and Arc (Po0.01). Each
bar is the mean7s.e.m. of n= 7–12 mice. *Po0.05; §§Po0.01; ***,§§§Po0.001. CUMS, chronic ultra-mild stress.
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posttranslational regulation in mice. In addition, postmortem brain
analysis also revealed a decreased expression of HDAC2 and H3K9
methylation, pointing toward a permissive state of chromatin, in
the nucleus accumbens of depressed patients.37 In the periphery,
mRNA proﬁling in white blood cells revealed a downregulation of
HDAC2 and HDAC5 in the depressive state of major depressive
disorder. These alterations at HDAC2 were normalized in the
remitted state,38 indicating that HDAC2 could represent a suitable
biomarker for mood disorders.
Further, we showed that transcripts encoding trophic factors
(Bdnf, Gdnf, Igf1), pro-survival factor (Bcl2), differentiation factor
(Neurod1) and cell/dendritic growth factor (Arc), known to be
critical in neuronal plasticity, were increased after chronic mild
stress, when compared with non-stressed mice. Hence, our
neurobiological investigations demonstrated the occurrence of
marked molecular and cellular changes underlying increased
hippocampal plasticity in CUMS-exposed mice. These results are
rather provocative because it is generally admitted that chronic
stress paradigms in rodents is associated with impaired synaptic
integrity, reduced dendritic arborization and decreased neurogen-
esis in the hippocampus, as well as depressive- and anxiety-like
behaviors.39,40 However, few studies reported that chronic stress
could also enhance neurogenesis, as well as dendritic spines and
excrescence in CA3 neurons of the hippocampus.40,41 In our CUMS
conditions—in contrast to other protocols using longer and/or
stronger stressors—we used a repetition of low-intensity socio-
environmental stressors for a total period of 3 weeks suggesting
that the timing, duration and intensity of the stressors might be
critical for triggering adaptive neuroendocrine and behavioral
outcomes. Furthermore, using the same stress procedure, we
previously reported a reduced expression of hippocampal GR
mRNA in CUMS mice.19 Interestingly, other reports, using different
models of exposure to chronic stress, showed that GR down-
regulation either via genetic knockdown or pharmacological
blockade, might be associated with increased synaptic
plasticity.42,43
Effect of agomelatine treatment on stress-related alterations
Agomelatine is an antidepressant that acts as a melatonergic
(MT1/MT2) agonist and a 5-HT2C antagonist.12 Like most
antidepressant drugs, agomelatine was shown to positively
modulate neurogenesis, hippocampal plasticity and neurotrophic
signaling in various rodent models of depression or after
stress.16,22,44,45 Although in the present study, we did not identify
the cell types that expressed the genes modiﬁed either by stress
and/or agomelatine treatment, it can be noticed that both the
glucocorticoid receptors, GRs, and the agomelatine targets, MT1/
MT2 and 5-HT2C, are present on CA1, CA3 and DG hippocampal
neurons, which also expressed the genes regulated by stress and
antidepressant treatments.46 However, previous studies have
pointed out the granule cells of the ventral part of the DG as a
main target for agomelatine effects,16 although our data also show
CA1 and CA3 to be regulated by stress and/or agomelatine in line
in part with Mairesse et al.47 Further studies should be addressed
to carefully characterize the cell type(s) involved in these effects.
Interestingly, in our studies, we did not observe any effect of
chronic agomelatine treatment on the expression of hippocampal
plasticity markers in non-stressed mice. Interestingly, agomelatine
speciﬁcally normalized the hippocampal alterations induced by
chronic mild stress, indicating that this drug exerts a disease-
dependent action on neuronal activity. MT2 receptors, one of
agomelatine’s targets, are abundantly expressed in various
hippocampal cell populations.13 Agomelatine could normalize
neuronal activity, as speciﬁcally indicated with c-Fos levels in the
prenatal stress model.47 Such effects might account, at least partly,
for agomelatine-induced normalization of the increased intracel-
lular signaling and associated epigenetic and neuroplastic
changes observed in CUMS-exposed mice. Such normalizing
effects have not been reported elsewhere, probably because only
few studies have investigated the action of antidepressants or
mood-stabilizing agents in rodent models exhibiting enhanced
hippocampal plasticity. Nevertheless, in line with our present data,
a recent study showed that ﬂuoxetine antagonizes the increased
locomotor activity and the changes in p-Creb, p-Erk and Bdnf in
the hippocampus after olfactory bulbectomy in mice.48 Similar
effects have been observed with lithium that reversed the
upregulation of Creb signaling induced by chronic stress.49
Furthermore, selective serotonin reuptake inhibitors or tricyclic
antidepressants were shown to modulate brain HDAC activity and
histone posttranslational modiﬁcations in animal models of
depression or stress.11 Here, we showed that agomelatine could
similarly correct the altered HDAC2 levels, as well as posttransla-
tional modiﬁcations at histone tails (for example, H3K27me3 and
H3K9/14ac) in adult mice subjected to prolonged exposure to
stress, an action that was causally related to behavioral remission.
Altogether, these observations support the hypothesis that the
reversal of chromatin-related alterations is required for the
therapeutic action of antidepressant drugs, as already
suggested.11
At the behavioral level, we know that chronic mild stress causes
reward, motivation and attention deﬁcits, symptoms related to
decreased mesolimbic dopaminergic activity. The behavioral
effects of agomelatine after chronic stress, which resulted in the
normalization of CUMS-induced hyperactivity and of affective and
cognitive defects, might be attributed to its antagonist action at 5-
HT2C receptors, as the 5-HT2C receptor blockade property of
agomelatine enhances dopamine release in the frontal cortex.50 In
line with the frequent association between catecholamines and
motor activity and the previous studies on agomelatine with
distinct models of mood disorder,47,51 agomelatine treatment was
also found here to normalize the CUMS-induced enhancement in
motor activity. Importantly, MT receptor-mediated control of
emotional reactivity and vigilance might also be involved in the
effects of agomelatine because the melatonergic receptor
antagonist S22153 antagonized the antidepressant-like effect of
agomelatine in animal models of depression.52
Altogether, our data suggest that the normalizing effects of
agomelatine on the neurobiological and behavioral dysfunctions
observed after chronic mild stress is attributed to its synergistic
action via the melatonergic agonist and 5-HT2C antagonist
properties, as already reported.16
Conclusions and perspectives
In summary, our neurobiological and behavioral investigations
provided clear-cut evidence that prolonged exposure of C57Bl/6
mice to socio-environmental stressors of low intensity can induce
marked molecular and cellular changes leading to increased
hippocampal plasticity, together with increased locomotor activity,
hyperarousal, anhedonia, distractibility and increased risk-
taking behaviors. Agomelatine effectively prevented both neuro-
chemical and behavioral alterations triggered by stress. In addition,
the observed epigenetic changes in the hippocampus suggest
that chromatin remodeling via histone modiﬁcations might
increase susceptibility to mood disorders, and that the reversal of
such changes by agomelatine is associated with its therapeutic
action.
The fact that the behavioral changes induced by CUMS closely
resembled symptoms usually observed in the manic state of
bipolar disorders is also interesting (see Supplementary Table S8).
The CUMS model as described in the present study might be of
particular interest to further investigate the possible implication of
stress, alterations in circadian activity rhythms and hippocampal
dysfunctions in the development of bipolar disorders. Although
no compelling evidence for an increased hippocampal
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intracellular signaling was reported in humans, validated models
of manic-like behaviors showed neurochemical changes, including
hippocampal upregulation of BDNF protein and increased PI3-K
and mitogen-activated protein kinases signaling,53,54 as found
here in CUMS mice. Future clinical studies, more particularly
postmortem brain analyses, should address whether changes of
the above-mentioned biomarkers occur in the hippocampus of
bipolar patients.
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